413results about "Haemofiltration" patented technology

Methods for aspiration to remove thrombus / clot material using a system configured to remove, filter and return clot. These methods allow the removal of clot material using a fluidically-driven aspiration device when attached to an aspiration catheter and proximate to obstructive clot material. A fluidic actuator drives an aspirator, which may be automatically controlled to apply a vacuum in a pattern to enhance clot removal and collection from the body as well as improve blood return using the same closed system. The fluidic actuator may direct the aspirated blood through a filter and deaerator to allow the filtered blood to be returned to the patient.

The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.

The present invention provides a method of removing microplastics from blood or body of a subject, including one or more tissues of the subject, by extracorporeal blood purification, including by plasma exchange, such as double filtration plasma exchange. The present invention also provides a method of treating medical conditions and methods of improving healthy lifespan and lifespan using extracorporeal blood purification, including plasma exchange, such as double filtration plasma exchange, such as by filtering microplastics from blood, and removing microplastics from a tissue or body of a subject, such as a human subject.

The present invention relates to systems and methods for optimizing plasma collection volume. A plasma withdrawal system and a method for operating a plasma withdrawal system are provided by which the volume / weight of the anticoagulated plasma collected is optimized. In one example, a nomogram is provided that utilizes the donor hematocrit to calculate the volume / weight of raw plasma within a plasma product having a maximum volume allowed by the FDA nomogram. In a plasma withdrawal process having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the increasing hematocrit of the donor, resulting in a greater total volume of plasma product to be collected during the plasma withdrawal process.

Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

The invention belongs to the technical field of medical equipment, and discloses a movable continuous blood purification first-aid device which comprises a movable seat and further comprises a stabilizing mechanism arranged in the inner wall of the bottom end of the movable seat; the blood purification barrel is fixedly connected to the outer wall of the top end of the movable seat, and a cover plate is arranged on the outer wall of the blood purification barrel; the cleaning mechanism is arranged in the inner wall of the blood purification barrel; the mounting mechanism is arranged on the outer wall of the bottom end of the blood purification barrel, and an impurity output pipe is arranged on the inner wall of the mounting mechanism; wherein the stabilizing mechanism comprises a stabilizing plate; through cooperation of the stabilizing plate, the pedal A and other structures, the stabilizing plate can be moved downwards and fixed by treading the pedal A downwards, the stabilizing plate is kept in a state of being in contact with the ground, the overall stability of the device is improved, and then it is guaranteed that in the using process, it is avoided that the device topples over due to external force collision, and the blood purification operation is affected.

Disposable set for an extracorporeal blood treatment apparatus including a blood circuit comprising a filtration unit, a blood withdrawal line including a blood pump tract configured to be engaged by a blood pump, a blood return line, and an infusion line extending between a first end connected to the blood withdrawal line upstream the blood pump tract, and a second end for connection to an infusion substance source: the blood pump tract is interposed between the filtration unit and the first end of the infusion line. The disposable set further comprises a pressure damper arranged towards or at the first end of the infusion line, the pressure damper being configured to prevent, or reduce an amount of, the access negative pressure to extend in the infusion line upstream the pressure damper.

Methods and apparatuses for blood clot aspiration. Described are fluid management components and assemblies for blood clot extraction from a patient's body and for filtering blood and recirculating blood back into the patient's body.

A blood treatment machine includes a patient comfort feedback mechanism configured to be adjusted by a patient to indicate comfort levels of the patient. The machine is configured to adjust one or more treatment parameters based on the patient feedback.

A semipermeable membrane comprises a sulfonated polyarylene ether copolymer and is sterilized with ethylene oxide gas. The sulfonated polyarylene ether copolymer includes a hydrophobic segment repeating unit represented by a formula (1) and a hydrophilic segment repeating unit represented by a formula (2) as copolymerization components.

This invention relates to a filter membrane and its preparation method, particularly to a platelet-rich suspension leukocyte-removing filter membrane and its preparation method. The method uses polyethersulfone (PES) material, which has stable mechanical properties, heat resistance, and chemical properties, as the core material, and polylactic acid (PLA) material, which has good biocompatibility and safety, as the outer material. A coaxial electrospinning process is employed to prepare the PES-PLA filter membrane. Furthermore, a vinylpyrrolidone-acrylamide copolymer is grafted onto the surface of the PES-PLA filter membrane. The resulting platelet-rich suspension leukocyte-removing filter membrane has a narrow pore size distribution, high porosity, and good hydrophilicity, biocompatibility, and antibacterial properties. It can effectively filter out leukocytes from platelet suspensions and reduce the risk of bacterial contamination.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

The invention relates to a therapeutic apheresis filter for eliminating heavy metals in blood and especially residual platinum in cancer patients after chemotherapy treatment. The filter comprises a casing (1) that can be coupled to an extracorporeal apheresis device and that has inlet and outlet openings (11a, 12a) for circulating therein blood or plasma extracted from a patient and that delimits a cavity containing a biomaterial (3), made up of granulated or powdered egg membrane particles for retaining the heavy metal molecules inside the filter by adsorption. The invention further comprises a method using the apheresis filter with egg membrane as a biomaterial to eliminate heavy metals in blood.

A shunt for use with a first conduit and a second conduit comprises a first housing configured to receive the first conduit for blood ingress such that the first conduit extends through the first housing, the first housing being shaped to define a slot; a trigger lever movably mounted in the first housing and extending out of the slot such that a depression of the trigger lever causes the trigger lever to depress the first conduit, thereby controlling blood flow rate through the first conduit; and a second housing removably attachable to the first housing, the second housing comprising a cavity for receiving and holding blood from the first conduit, and configured to receive the second conduit such that the second conduit is in communication with the cavity for blood egress through the second conduit.

Compounds, systems, kits, methods, and / or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and / or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and / or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

The present disclosure relates to devices, e.g, extracorporeal blood purification (EBP) devices, which comprise a cartridge or sorbent comprising a cellular membrane derived from a cell. The present disclosure also relates methods for removing or reducing a substance, e.g, an undesirable substance, from a fluid, e.g, a subject's blood, using the devices or EBP devices.

A hemodiafiltration system with a disposable pumping unit is disclosed. An example system includes a medical fluid pump actuator, a medical fluid heater, a blood filter and a disposable unit. The example disposable unit includes a medical fluid cassette portion including a medical fluid cassette housing configured to be operatively connected to the medical fluid pump actuator to pump medical fluid through the medical fluid cassette portion when the medical fluid cassette portion is in fluid communication with a medical fluid source. The example medical fluid cassette portion is also configured to be placed in fluid communication with the blood filter and with an extracorporeal circuit communicating with the blood filter, the fluid communication enabling hemodiafiltration to be performed. The example disposable unit also includes a heater bag configured to be placed in operable communication with the medical fluid heater and in fluid communication with the medical fluid cassette portion.

The present disclosure relates to Oxygen Reduction Disposable kits (ORDKit), devices and methods for the improved preservation of whole blood and blood components. The improved devices and methods for the collection of blood and blood components provide for whole blood and blood components having reduced levels of oxygen. The devices and methods provide for the rapid preparation of deoxygenated blood and blood components for storage that improves the overall quality of the transfused blood and improves health outcomes in patients.

A method for collecting blood components, comprising: separating a first amount of plasma from whole blood; separating a total amount of collectable platelets from whole blood available after separating the first amount of plasma; if the total collection amount after the separation of the total amount of platelets is less than a maximum value adjusted by real-time data related to collection, then separating a second amount of plasma from the whole blood available after the separation of the total amount of platelets, and then separating a total amount of erythrocytes from the whole blood available after the separation of the second amount of plasma; and if the total collection amount is at a maximum adjusted by the real-time data relating to the collection, separating a total amount of red blood cells from the whole blood available after separating the total amount of platelets.

The artificial diuretic device is wearable by a patient (H) and comprises a reusable machine (2) and a disposable unit (3), which is completely filled with a treatment liquid (Lt) before use.

The present invention relates to a method for diafiltration using a crossflow filtration unit for the continuous diafiltration of a food liquid to obtain a retentate and a permeate.

A multi-layered bio purifier includes a plurality of layers. Each layer may include a membrane having a first side and a second side opposite the first side, a first channel formed on the first side, and a second channel formed on the second side. Further, each layer may include a first type of cells formed on the first side in the first channel and a second type of cells formed on the second side in the second channel. The multi-layered bio purifier includes a first manifold assembly to split incoming blood into the first channel and the second channel of the plurality of layers and a second manifold assembly to combine processed blood from the first channel and the second channel of the plurality of layers. The processed blood may include detoxified or purified blood.

An EBDLR system includes a multi-layered bio purifier having a plurality of layers. Each layer includes a membrane, a first type of cells on a first side of the membrane in a first channel, and a second type of cells on a second side of the membrane in a second channel. The EBDLR includes a plasma separator to receive blood from a subject and separate a plasma component from the blood, a first reservoir to collect the plasma component, and a second pump to move the plasma component from the first reservoir to the multi-layered bio purifier. The multi-layered bio purifier distributes the plasma component into the first and second channels of each layer to purify the plasma component. The EBDLR includes a second reservoir to collect the purified plasma component and a third pump to infuse the purified plasma component from the second reservoir into the subject.

The present subject matter relates to systems and methods for syringe-free blood return in a dialysis machine blood circuit. A three-way connector can include a first inlet configured to be connected to a patient arterial access line, a second inlet connected to a substitution fluid line, and an outlet connected to a machine arterial line. In this arrangement, the three-way connector is configured to selectively allow a flow of substitution fluid from the substitution line into the machine arterial line and / or into the patient arterial access line without changing the connections of tubing within the circuit.

There is provided a blood purification apparatus in which blood remaining in a blood circuit can be smoothly returned to a patient's body even if a blood flow route is clogged or narrowed at the time of blood return, with no need of reconnection of a line for supplying substitution fluid during blood return. A blood purification apparatus includes a physiological-saline supply line (La) connected to an upstream position in a removal-side blood circuit (1a) and through which substitution fluid is allowed to be supplied to a blood circuit (1) at the time of blood return; a pre-substitution line (L2c) and a post-substitution line (L2d) connected to respective downstream positions in the blood circuit (1) and through which the substitution fluid is allowed to be supplied to the blood circuit (1) at the time of blood return, the downstream positions being different from the upstream position; a clogging-identifying unit (7) configured to identify any clogging position of a blood flow route in the blood circuit (1) or a dialyzer (2) with reference to pressures detected by pressure-detecting units (S1 to S3); and a control unit (11) configured to switch from one of a removal-side substitution-fluid supply line and a return-side substitution-fluid supply line to the other at the time of blood return if a clogging position is identified by the clogging-identifying unit (7).

The utility model discloses an artery pot device and a blood purification device, and the artery pot device comprises a bottle body, the interior of the bottle body is hollow, a liquid inlet and a liquid outlet which are communicated with the interior of the bottle body are formed in the lower part of the bottle body, and a cylinder is arranged in the bottle body; the sleeve is rotationally arranged on the periphery of the cylinder along the vertical axis, the sleeve is in clearance fit with the cylinder, one end of the sleeve extends towards the bottom of the bottle body, and the other end of the sleeve extends towards the top of the bottle body; the stirring part comprises a plurality of blade sets, the blade sets are distributed in the axial direction of the sleeve, each blade set comprises a plurality of blades distributed in the circumferential direction of the sleeve, and the height of the first blade set corresponds to that of the liquid inlet, so that blood flowing in from the liquid inlet acts on the blades of the first blade set, and the first blade set is driven to rotate. The risk of blood coagulation in the arterial kettle can be reduced, replacement liquid injected for hemodiafiltration treatment can be fully mixed with blood, and the safety of blood purification treatment is improved.

The disclosure relates to a modular blood treatment device (2) with several modules (12, 14, 16, 18, 20, 22) which are configured to be detachably coupled together for performing blood treatment on a patient (10). A main control unit (26) is configured to control the coupled modules (12, 14, 16, 18, 20, 22) for performing the blood treatment. The blood treatment device (2) has sensors (88, 96; 114, 116, 132, 133, 165, 167, 168; 186, 190, 192) and actuators (82, 86, 94, 100, 102; 111, 113, 120-130; 140, 148, 150, 152-158; 162-164; 174-178; 182, 194, 196). At least two of the modules (12, 14, 16, 18, 20, 22) are designed as self-controlling modules, each comprising as components at least one of the actuators (82, 86, 94, 100, 102; 111, 113, 120-130; 140, 148, 150, 152-158; 162-164; 174-178; 182, 194, 196) and at least one module control unit (106, 135, 160, 170, 180, 200).The module control units (106, 135, 160, 170, 180, 200) are configured to control at least one actuator of the same self-control module, to detect a predetermined state change of the self-control module (12, 14, 16, 18, 20, 22) belonging to the respective module control unit (106, 135, 160, 170, 180, 200), to send a corresponding module state change message directly to at least one other module control unit (106, 135, 160, 170, 180, 200) upon detection of the predetermined state change, to receive a module state change message directly from at least one other module control unit (106, 135, 160, 170, 180, 200), and upon receiving a Module state change message from at least one other module control unit to instruct at least one actuator of the same self-control module (12, 14, 16, 18, 20, 22) to perform a predetermined action.